Phase i study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors

Devalingam Mahalingam*, John J. Nemunaitis, Laeeq Malik, John Sarantopoulos, Steven Weitman, Kamalesh Sankhala, Jessica Hart, Ahmed Kousba, Nicole S. Gallegos, Gavin Anderson, John Charles, Jon M. Rogers, Neil N. Senzer, Alain C. Mita

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Purpose: ATI-1123 is a liposomal formulation of docetaxel and may be administered without the premedications and hypersensitivity reactions. This Phase I study examines the safety, tolerability, pharmacokinetics (PKs), and antitumor activity of ATI-1123. Methods: Patients with advanced solid malignancies received escalating doses of ATI-1123 intravenously over 1-h every 3 weeks. The dosing commenced using an accelerated titration design and was followed by a modified 3 + 3 Fibonacci schema to determine maximally tolerated dose (MTD). Plasma was analyzed for encapsulated/non-encapsulated docetaxel; PK analyses were performed using model independent method. Response was assessed using RECIST criteria. Results: In total, 29 patients received doses ranging from 15 to 110 mg/m2. At 110 mg/m2, two of six patients experienced dose-limiting toxicities including grade 3 stomatitis and febrile neutropenia. The 90 mg/m2 cohort was expanded to ten patients and identified as the MTD. The most common adverse events were fatigue, nausea, neutropenia, anemia, anorexia, and diarrhea. ATI-1123 exhibited linear and dose proportional PKs. One patient with lung cancer had confirmed partial response, and stable disease was observed in 75 % patients. Conclusions: ATI-1123 demonstrated an acceptable tolerability and favorable PK profile in patients with solid tumors. Our results provide support for Phase II trials to determine the antitumor activity of this drug.

Original languageEnglish (US)
Pages (from-to)1241-1250
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Issue number6
StatePublished - Dec 2014


  • ATI-1123
  • Docetaxel
  • Pharmacokinetics
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Phase i study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors'. Together they form a unique fingerprint.

Cite this